BGACF (BioNeutra Global) Debt-to-Equity: -0.92 (As of Sep. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is BioNeutra Global Debt-to-Equity?

BioNeutra Global BGACF Debt-to-Equity is -0.92 as of Sep. 2024.

BioNeutra Global's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.69 Mil. BioNeutra Global's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $4.88 Mil. BioNeutra Global's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $-6.08 Mil. BioNeutra Global's debt to equity for the quarter that ended in Sep. 2024 was -0.92.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for BioNeutra Global's Debt-to-Equity or its related term are showing as below:

BGACF's Debt-to-Equity is not ranked *
in the Consumer Packaged Goods industry.
Industry Median: 0.42
* Ranked among companies with meaningful Debt-to-Equity only.

BioNeutra Global  (OTCPK:BGACF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

BioNeutra Global Debt-to-Equity Related Terms

BioNeutra Global Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for BioNeutra Global's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioNeutra Global Debt-to-Equity Chart

BioNeutra Global Annual Data
Trend Feb14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.60 10.10 -6.67 -1.87 -1.23

BioNeutra Global Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.95 -1.23 -1.09 -0.97 -0.92

BGACF vs ARRT, BSFC, RTON: Debt-to-Equity Comparison

For the Packaged Foods subindustry, BioNeutra Global's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioNeutra Global Debt-to-Equity vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, BioNeutra Global's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where BioNeutra Global's Debt-to-Equity falls into.


BioNeutra Global Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

BioNeutra Global's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.345 + 5.35) / -4.617
=-1.23

BioNeutra Global's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.689 + 4.879) / -6.076
=-0.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of -0.92 mean?
BioNeutra Global (BGACF) has a Debt-to-Equity of -0.92 as of Sep. 2024. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on BioNeutra Global and its competitors.
Is BioNeutra Global's Debt-to-Equity too high?
BioNeutra Global's current Debt-to-Equity is -0.92.
How does BioNeutra Global's Debt-to-Equity compare to ARRT and BSFC?
BioNeutra Global's Debt-to-Equity of -0.92 can be compared against companies in the Consumer Packaged Goods industry. The industry median Debt-to-Equity is 0.42. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Consumer Packaged Goods company?
The median Debt-to-Equity among Consumer Packaged Goods companies is 0.42, based on 1,746 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on BioNeutra Global and its competitors. For the Consumer Packaged Goods industry, the median Debt-to-Equity is 0.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioNeutra Global's current Debt-to-Equity is -0.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNeutra Global stock overvalued right now?
BioNeutra Global (BGACF) has a current Debt-to-Equity of -0.92. The current Debt-to-Equity is -0.92. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For BioNeutra Global (BGACF), the current Debt-to-Equity is -0.92 as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioNeutra Global Business Description

Address 1101-1030 West Georgia Street, Vancouver, BC, CAN, V6E 2Y3
BioNeutra Global Corp is engaged in the research, development, production, and commercialization of food ingredients for neutraceutical, functional and mainstream foods, focusing on oligosaccharides. Its product portfolio provides ingredients for various food systems, that contribute to human nutrition and wellness in functional and healthy foods. Its prime product, VitaFiber IMO, is offered in both powder and syrup form. The company operates in Canada while generating sales revenue from various countries internationally. It has a single industry segment, manufacturing and trading of products. The majority of the revenue is derived from the United States.